{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:24:01Z","timestamp":1784118241808,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","award":["PALM Research Project"],"award-info":[{"award-number":["PALM Research Project"]}],"id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01798-3","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T03:05:50Z","timestamp":1776654350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013"],"prefix":"10.1186","volume":"19","author":[{"given":"Franco","family":"Locatelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Buldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pigazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Rizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Menna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Fagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Tumino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Lo Nigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppina","family":"Cefalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Paganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Strocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Becilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Giagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Micalizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Masetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"2","key":"1798_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood-2013-03-491621","volume":"122","author":"A Pession","year":"2013","unstructured":"Pession A, Masetti R, Rizzari C, et al. Results of the AIEOP AML 2002\/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013;122(2):170\u20138.","journal-title":"Blood"},{"issue":"1","key":"1798_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2013-02-484097","volume":"122","author":"U Creutzig","year":"2013","unstructured":"Creutzig U, Zimmermann M, Bourquin JP, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood. 2013;122(1):37\u201343.","journal-title":"Blood"},{"issue":"7","key":"1798_CR3","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","volume":"105","author":"R Aplenc","year":"2020","unstructured":"Aplenc R, Meshinchi S, Sung L, et al. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group. Haematologica. 2020;105(7):1879\u201386.","journal-title":"Haematologica"},{"issue":"24","key":"1798_CR4","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1200\/JCO.2008.18.7948","volume":"27","author":"I Tsukimoto","year":"2009","unstructured":"Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27(24):4007\u201313.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1798_CR5","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1182\/blood-2012-03-416701","volume":"120","author":"H Hasle","year":"2012","unstructured":"Hasle H, Abrahamsson J, Forestier E, et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood. 2012;120(5):978\u201384.","journal-title":"Blood"},{"issue":"27","key":"1798_CR6","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","volume":"33","author":"CM Zwaan","year":"2015","unstructured":"Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015;33(27):2949\u201362.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1798_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/leu.2016.177","volume":"31","author":"E Manara","year":"2017","unstructured":"Manara E, Basso G, Zampini M, et al. Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Leukemia. 2017;31(1):18\u201325.","journal-title":"Leukemia"},{"issue":"1","key":"1798_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3324\/haematol.2021.280250","volume":"108","author":"S Noort","year":"2023","unstructured":"Noort S, Oosterwijk JV, Ma J, et al. Analysis of rare driving events in pediatric acute myeloid leukemia. Haematologica. 2023;108(1):48\u201360.","journal-title":"Haematologica"},{"issue":"4","key":"1798_CR9","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/leu.2016.361","volume":"31","author":"V Bisio","year":"2017","unstructured":"Bisio V, Zampini M, Tregnago C, et al. NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group. Leukemia. 2017;31(4):974\u20137.","journal-title":"Leukemia"},{"issue":"17","key":"1798_CR10","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1182\/blood-2012-11-469825","volume":"121","author":"R Masetti","year":"2013","unstructured":"Masetti R, Pigazzi M, Togni M, et al. CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood. 2013;121(17):3469\u201372.","journal-title":"Blood"},{"issue":"1","key":"1798_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bjh.14523","volume":"177","author":"B Buldini","year":"2017","unstructured":"Buldini B, Rizzati F, Masetti R, et al. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002\/01 study protocol. Br J Haematol. 2017;177(1):116\u201326.","journal-title":"Br J Haematol"},{"issue":"6","key":"1798_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","volume":"11","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543\u201352.","journal-title":"Lancet Oncol"},{"issue":"16","key":"1798_CR13","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.22.02120","volume":"41","author":"RE van Weelderen","year":"2023","unstructured":"van Weelderen RE, Klein K, Harrison CJ, et al. Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia: a study by the International Berlin-Frankfurt-Munster study group. J Clin Oncol. 2023;41(16):2963\u201374.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1798_CR14","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/leu.2013.339","volume":"28","author":"E Manara","year":"2014","unstructured":"Manara E, Bisio V, Masetti R, et al. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002\/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia. 2014;28(5):1132\u20134.","journal-title":"Leukemia"},{"issue":"2","key":"1798_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/bmt.2014.246","volume":"50","author":"F Locatelli","year":"2015","unstructured":"Locatelli F, Masetti R, Rondelli R, et al. Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002\/01 study. Bone Marrow Transplant. 2015;50(2):181\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1798_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/cyto.b.21518","volume":"94","author":"MN Dworzak","year":"2018","unstructured":"Dworzak MN, Buldini B, Gaipa G, et al. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2018;94(1):82\u201393.","journal-title":"Cytometry B Clin Cytom"},{"issue":"18","key":"1798_CR17","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1182\/blood-2012-09-454454","volume":"120","author":"M Pigazzi","year":"2012","unstructured":"Pigazzi M, Manara E, Bisio V, et al. Screening of novel genetic aberrations in pediatric acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Blood. 2012;120(18):3860\u20132.","journal-title":"Blood"},{"issue":"3","key":"1798_CR18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/leu.2010.316","volume":"25","author":"M Pigazzi","year":"2011","unstructured":"Pigazzi M, Masetti R, Bresolin S, et al. MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia. 2011;25(3):560\u20133.","journal-title":"Leukemia"},{"issue":"12","key":"1798_CR19","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party. Blood. 2018;131(12):1275\u201391.","journal-title":"Blood"},{"key":"1798_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00412","volume":"7","author":"B Buldini","year":"2019","unstructured":"Buldini B, Maurer-Granofszky M, Varotto E, Dworzak MN. Flow-cytometric monitoring of minimal residual disease in pediatric patients with acute myeloid leukemia: recent advances and future strategies. Front Pediatr. 2019;7:412.","journal-title":"Front Pediatr"},{"issue":"4","key":"1798_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"key":"1798_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2020-139189","volume":"136","author":"K Waack","year":"2020","unstructured":"Waack K, Schneider M, Walter C, et al. Improved outcome in pediatric AML - the AML-BFM 2012 study. Blood. 2020;136:3.","journal-title":"Blood"},{"issue":"27","key":"1798_CR23","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","volume":"32","author":"AS Gamis","year":"2014","unstructured":"Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531. J Clin Oncol. 2014;32(27):3021\u201332.","journal-title":"J Clin Oncol"},{"key":"1798_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1182\/blood-2023-181593","volume":"142","author":"A Moore","year":"2023","unstructured":"Moore A, Maycock S, Leverger G, et al. Outcomes for children with high risk acute myeloid leukemia on the Myechild 01 international phase III clinical trial. Blood. 2023;142:5.","journal-title":"Blood"},{"issue":"18","key":"1798_CR25","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1200\/JCO.23.01841","volume":"42","author":"A Tierens","year":"2024","unstructured":"Tierens A, Arad-Cohen N, Cheuk D, et al. Mitoxantrone versus liposomal daunorubicin in induction of pediatric AML with risk stratification based on flow cytometry measurement of residual disease. J Clin Oncol. 2024;42(18):2174\u201385.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1798_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41375-023-02075-9","volume":"38","author":"D Tomizawa","year":"2024","unstructured":"Tomizawa D, Matsubayashi J, Iwamoto S, et al. High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia. Leukemia. 2024;38(1):202\u20136.","journal-title":"Leukemia"},{"issue":"23","key":"1798_CR27","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1200\/JCO.19.00327","volume":"37","author":"JE Rubnitz","year":"2019","unstructured":"Rubnitz JE, Lacayo NJ, Inaba H, et al. Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: the AML08 multicenter, randomized phase III trial. J Clin Oncol. 2019;37(23):2072\u201381.","journal-title":"J Clin Oncol"},{"key":"1798_CR28","doi-asserted-by":"crossref","unstructured":"Becilli M, Merli P, Algeri M et al. Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed\/refractory acute myeloid leukemia. Blood 2026.","DOI":"10.1182\/blood.2025032299"},{"issue":"8","key":"1798_CR29","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/JCO-24-01715","volume":"43","author":"C Tregnago","year":"2025","unstructured":"Tregnago C, Benetton M, Ries RE, et al. Influence of nucleophosmin (NPM1) genotypes on outcome of patients with AML: an AIEOP-BFM and COG-SWOG intergroup collaboration. J Clin Oncol. 2025;43(8):972\u201384.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1798_CR30","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1038\/s41375-024-02368-7","volume":"38","author":"B Cuglievan","year":"2024","unstructured":"Cuglievan B, Kantarjian H, Rubnitz JE, et al. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia. 2024;38(10):2073\u201384.","journal-title":"Leukemia"},{"issue":"11","key":"1798_CR31","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1002\/ajh.70056","volume":"100","author":"P Merli","year":"2025","unstructured":"Merli P, Masetti R, Pigazzi M, et al. Sensitivity of pediatric myelodysplastic syndromes with excess of blasts with UBTF -TD to venetoclax\/azacitidine. Am J Hematol. 2025;100(11):2160\u20134.","journal-title":"Am J Hematol"},{"issue":"13","key":"1798_CR32","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1182\/bloodadvances.2023012041","volume":"8","author":"R Masetti","year":"2024","unstructured":"Masetti R, Baccelli F, Leardini D, Locatelli F. Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies? Blood Adv. 2024;8(13):3583\u201395.","journal-title":"Blood Adv"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01798-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01798-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01798-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T01:59:43Z","timestamp":1780279183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01798-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1798"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01798-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethical Committees of Bambino Ges\u00f9 Children\u2019s Hospital and thereafter by each participating center. Informed written consent was obtained before enrolment in accordance with regulatory guidelines. Written informed consent was obtained by both parents or legal representatives; minors above the age of 12 were required to provide written assent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FL is on the advisory board for Amgen, Novartis, Sanofi, Vertex; speaker\u2019s bureau for Miltenyi Biomedicine, Amgen, Novartis, Bristol Myers Squibb, Gilead, SOBI. CR reports receipt of grants\/research supports from SERB, honoraria or consultation fees from AMGEN, CLINIGEN, JAZZ, SERVIER, SERB, and speaker\u2019s bureau for JAZZ. PM has received consulting fee from SOBI, Miltenyi, Amgen, and Pierre Fabre.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}